Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Rating) have been assigned an average recommendation of "Hold" from the thirteen brokerages that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and two have given a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $101.70.
A number of equities research analysts have commented on the company. Cowen lowered their target price on Tandem Diabetes Care from $141.00 to $107.00 in a report on Thursday, August 4th. Piper Sandler lowered their target price on Tandem Diabetes Care from $120.00 to $80.00 and set an "overweight" rating on the stock in a report on Thursday, August 4th. StockNews.com cut Tandem Diabetes Care from a "hold" rating to a "sell" rating in a report on Friday. Lake Street Capital reduced their price target on Tandem Diabetes Care from $200.00 to $150.00 in a research note on Thursday, August 4th. Finally, Cowen reduced their price target on Tandem Diabetes Care from $141.00 to $107.00 in a research note on Thursday, August 4th.
Get Tandem Diabetes Care alerts:Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in TNDM. Fifth Third Bancorp raised its position in shares of Tandem Diabetes Care by 358.3% in the 2nd quarter. Fifth Third Bancorp now owns 440 shares of the medical device company's stock worth $26,000 after buying an additional 344 shares during the period. Quadrant Capital Group LLC raised its position in shares of Tandem Diabetes Care by 244.7% in the 2nd quarter. Quadrant Capital Group LLC now owns 517 shares of the medical device company's stock worth $31,000 after buying an additional 367 shares during the period. Exane Derivatives purchased a new position in shares of Tandem Diabetes Care in the 1st quarter worth $33,000. Byrne Asset Management LLC purchased a new position in Tandem Diabetes Care in the fourth quarter valued at about $34,000. Finally, CI Investments Inc. raised its position in Tandem Diabetes Care by 10,566.7% in the first quarter. CI Investments Inc. now owns 320 shares of the medical device company's stock valued at $37,000 after purchasing an additional 317 shares during the period. 95.28% of the stock is owned by hedge funds and other institutional investors.
Tandem Diabetes Care Stock Performance
Shares of NASDAQ:TNDM opened at $55.98 on Friday. The business's fifty day moving average price is $55.47 and its two-hundred day moving average price is $78.24. The company has a current ratio of 6.00, a quick ratio of 5.36 and a debt-to-equity ratio of 0.63. Tandem Diabetes Care has a one year low of $42.90 and a one year high of $155.86.About Tandem Diabetes Care
(Get Rating)
Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.
Read More
- Get a free copy of the StockNews.com research report on Tandem Diabetes Care (TNDM)
- MarketBeat: Week in Review 9/5 – 9/9
- Prepare For A Record-Setting Quarter For Cyber Security Stocks
- The Auto Market Is Slowly Recovering, These Stocks May Outperform
- Is DocuSign On The Verge Of A Major Reversal?
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.